SABCS 2017 - Annual San Antonio Breast Cancer Symposium
Dec 05 - Dec 09, 2017 | San AntonioTXUS
LARVOL is not affiliated with Annual San Antonio Breast Cancer Symposium and all trademarks, logos, and brand names are property of their respective owners
Showing 243 abstracts linked to Trials
Phase II, open label, randomized, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with operable or locally advanced/Inflammatory HER2-positive breast cancer. ImmunHER trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)
Efficacy and safety of abemaciclib in patients with liver metastases in the MONARCH 1, 2, and 3 studies
Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life "ESME" cohort
MonarchE: A randomized, open-label, phase 3 study of abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone in patients with high risk, node positive, early stage, HR+, HER2- breast cancer
Results from a randomized placebo-controlled phase 2 trial evaluating exemestane ± enzalutamide in patients with hormone receptor–positive breast cancer
A phase Ib study of oral administration of lucitanib in combination with fulvestrant in patients with HR+ metastatic breast cancer (mBC)
A randomized phase II trial evaluating the endocrine activity and efficacy of neoadjuvant degarelix versus triptorelin in premenopausal patients receiving letrozole for primary endocrine responsive breast cancer (TREND; IBCSG 41-13)
Abemaciclib tablet formulation is bioequivalent to capsules
Effects of neratinib after trastuzumab-based adjuvant therapy in hormone receptor-positive HER2+ early-stage breast cancer: Exploratory analyses from the phase III ExteNET trial
Timing of initiation of neratinib after completion of trastuzumab-based adjuvant therapy in early-stage HER2+ breast cancer: Exploratory analyses from the phase III ExteNET trial
Incidence and management of diarrhea with adjuvant pertuzumab and trastuzumab in HER2-Positive breast cancer
Neratinib in the extended adjuvant treatment of patients from Asia with early-stage HER2+ breast cancer after trastuzumab-based therapy: Exploratory analyses from the phase III ExteNET trial
Quality of life and patient-reported outcomes in US patients enrolled in the MONALEESA-2 study
An open-label, multicenter phase 1b trial of radium-223 + paclitaxel in cancer patients with bone metastases: Safety results from the breast cancer patient subgroup
Diffusion-weighted MRI improves imaging prediction of response in the I-SPY 2 trial